ViaCyte to Present at Upcoming Healthcare Events

Feb 17, 2016, 09:00 ET from ViaCyte, Inc.

SAN DIEGO, Feb. 17, 2016 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.

Details of the presentations are as follows:

Event:        

Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic

Title:           

Development of Stem-Cell Derived, Macroencapsulated Islet Replacement for Type 1 Diabetes

Speaker:      

Dr. Thomas Schulz, Director, ES Cell Technology

Date/Time:     

February 22, 2:35 p.m. EST

Location:        

New York Academy of Sciences Conference Center, New York, NY



Event:             

The 2nd Saudi International Biotechnologies Conference 2016

Title:               

Chasing a Cure for Type 1 Diabetes: The Development of a Stem Cell Derived Islet Replacement Therapy

Speaker:         

Dr. Paul Laikind, President and CEO

Date/Time:     

February 23, 9:15 a.m. AST

Location:        

KACST Headquarters, Conference Hall, Riyadh, Saudi Arabia



Event:             

American Society of Transplantation: Pipeline Presenters

Speaker:         

Dr. Kevin D'Amour, Vice President, Research and CSO

Date/Time:     

February 25, 11:00 a.m. MST

Location:        

Arizona Biltmore, Phoenix, Arizona

ViaCyte's VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes.  More info on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.

For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte's VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

For more information please visit www.viacyte.com.  Connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.

Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a

 

SOURCE ViaCyte, Inc.



RELATED LINKS

http://www.viacyte.com